Evidence map›Paper›PMID 39833471›Full record

ArticleNature structural & molecular biology2025

The structure and function of the ghrelin receptor coding for drug actions.

Yuki Shiimura, Dohyun Im, Ryosuke Tany, Hidetsugu Asada, Ryoji Kise, Eon Kurumiya, Hideko Wakasugi-Masuho, Satoshi Yasuda, Kazuma Matsui, Jun-Ichi Kishikawa and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature structural & molecular biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Beyond Hunger: The Structure, Signaling, and Systemic Roles of Ghrelin.International journal of molecular sciences · 2025
    Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Yuki Shiimura *Division of Molecular Genetics, Institute of Life Science, Kurume University, Fukuoka, Japan. shiimura_yuuki@kurume-u.ac.jp.ORCID http://orcid.org/0000-0002-9752-7399
Dohyun Im *Department of Cell Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID http://orcid.org/0000-0002-6939-7718
Ryosuke Tany *Pediatrics and Rare Diseases Group, Sanford Research, Sioux Falls, SD, USA.
Hidetsugu AsadaDepartment of Cell Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Ryoji KisePediatrics and Rare Diseases Group, Sanford Research, Sioux Falls, SD, USA.
Eon KurumiyaPediatrics and Rare Diseases Group, Sanford Research, Sioux Falls, SD, USA.
Hideko Wakasugi-MasuhoPediatrics and Rare Diseases Group, Sanford Research, Sioux Falls, SD, USA.
Satoshi YasudaDepartment of Chemistry, Graduate School of Science, Chiba University, Chiba, Japan.ORCID http://orcid.org/0000-0003-3555-1083
Kazuma MatsuiDivision of Molecular Genetics, Institute of Life Science, Kurume University, Fukuoka, Japan.ORCID http://orcid.org/0009-0007-0113-8449
Jun-Ichi KishikawaInstitute for Protein Research, Osaka University, Osaka, Japan.ORCID http://orcid.org/0000-0003-3913-7330
Takayuki KatoInstitute for Protein Research, Osaka University, Osaka, Japan.ORCID http://orcid.org/0000-0002-8879-6685
Takeshi MurataDepartment of Chemistry, Graduate School of Science, Chiba University, Chiba, Japan.ORCID http://orcid.org/0000-0002-5748-4670
Masayasu KojimaDivision of Molecular Genetics, Institute of Life Science, Kurume University, Fukuoka, Japan.ORCID http://orcid.org/0000-0002-3153-0341
So IwataDepartment of Cell Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan. s.iwata@mfour.med.kyoto-u.ac.jp.ORCID http://orcid.org/0000-0003-1735-2937
Ikuo MasuhoPediatrics and Rare Diseases Group, Sanford Research, Sioux Falls, SD, USA. Ikuo.Masuho@SanfordHealth.org.ORCID http://orcid.org/0000-0001-8754-987X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drugs targeting the ghrelin receptor hold therapeutic potential in anorexia, obesity and diabetes. However, developing effective drugs is challenging. To tackle this common issue across a broad drug target, this study aims to understand how anamorelin, the only approved drug targeting the ghrelin receptor, operates compared to other synthetic drugs. Our research elucidated the receptor's structure with anamorelin and miniG

Indexed as

Receptors, GhrelinAnimalsCrystallography, X-RayHumansLigandsModels, MolecularProtein BindingProtein ConformationSignal TransductionLigandsReceptors, Ghrelin

Identifiers

PMID39833471

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.